Summary
An accumulation of norepinephrin, serotonin and dopamin exists in the brainstem. A decrease of biogenic amines in the brains of Parkinson's cases has been demonstrated. A substitution by the precursor L-DOPA produces an increase of dopamin in the brain and a decrease of serotonin. The high level of dopamin improves the akinesia and the depletion of serotonin causes a toxic delir. A substitution by l-tryptophan restores the balance and the Dopa-psychosis disappears.
Similar content being viewed by others
References
Ajuriaguerra, J. de.: Symposium Bel-Air IV., Genève, Sept. 1970. Monoamines Noyaux gris centraux et Syndrome de Parkinson, p. 327–353. Paris: Masson. 1971.
Amin, A. M., T. B. B. Crawford, andJ. U. Gaddum: The distribution of 5 OH tryptamin and substance P in the central nervous system. Abstr. XIX int. physiol. Congr., p. 165 (1953).
Andńt, N. E., B. E. Ross, andB. Werdinius: On the Occurence of Homovanillic Acid in Brain and Cerebrospinal Fluid and its Determination by a Fluorometric Method. Life Science7, 448 (1963).
Anderson, M., andG. Guerra: Wahnsyndrome im Verlauf des encephalitischen Parkinson. Rass. Neuropsychiatr.5, 22–44 (1951).
Ashcroft, G. W., T. B. B. Crawford, D. Eccleston, D. Sharman, andD. F. McDougalb: 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatr. neurol. diseases. LancetII, 1049–1052 (1966).
Ashcroft, G. W., andD. F. Sharman: Drug-induced Changes in the Concentration of 5-OR Indolyl Compounds in Cerebrospinal Fluid and Caudate Nucleus. Brit. J. Pharmacol.19, 153–160 (1962).
Barbeau, A.: L-DOPA therapy in Parkinson's disease: a critical review of nine years' experience. Canad. Med. Assoc.101, 791–800 (1969).
Bartholini, G., H. M. Bates, W. P. Burkhard, andA. Pletscher: Increase of cerebral catecholamines by 3,4-dihydroxyphenylalanine after Inhibition of peripheral decarboxylase. Nature (London)215, 852–853 (1967).
Bartholini, G., M. Da Prada, andA. Pletscher: Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J. Pharm. Pharmac.20, 228–229 (1968).
Bernheimer, H., W. Birkmayer, andO. Hornykiewicz: Verteilung des 5-hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinsonsyndrom. Klin. Wsehr.39, 1056–1059 (1961).
Bernheimer, H., W. Birkmayer, andO. Hornykiewicz: Zur Biochemie dt Parkinson-Syndroms des Menschen. Klin. Wschr.41, 465–469 (1963)
Birkmayer, W., andO. Hornykiewicz: Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinese. Wien. klin. Wschr.73, 787–788 (1961).
Birkmayer, W., andO. Hornykiewicz: Der L-Dioxyphenylalanin (L-DOPA) Effekt beim Parkinsonsyndrom des Menschen. Arch. Psychiatr.203, 560–574 (1962).
Birkmayer, W.: Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien. Z. f. Nervenheilk.23, 128–139 (1966).
Birkmayer, W.: Die Bedeutung des Monoamin-Metabolismus für die Pathologie des extrapyramidalen Systems. Ars medici57, 814–825 (1967).
Birkmayer, W., andM. Mentasti: Weitere experimentelle Untersuchungen über den Catecholaminstoffwechsel bei extrapyramidalen Erkrankungen Arch. Psychiatr.210, 29–35 (1967).
Birkmayer, W.: Biochemistry of Depression in Parkinson's Disease. In:Barbeau, A., andF. H. McDowell (eds.) L-DOPA and Parkinsonism, p. 341–342. Philadelphia: Fa. Davis. 1970.
Birkmayer, W., andW. Linauer: Störung des Tyrosin- und Tryptophan-metabolimus bei Depression. Arch. Psychiatr. Nervenkr.213, 377–387 (1970).
Birkmayer, W.: 10 Jahre L-DOPA Therapie des Parkinsonsyndroms. Wien, klin. Wschr.83, 221–227 (1971).
Birkmayer, W., W. Danielczyk, E. Neumayer, andP. Riederer. (In press.)
Bostroem, A.: Zum Verständnis gewisser psychischer Veränderungen bei Kranken mit Parkinsonschem Symptomenkomplex. Z. ges. Neurol. Psychiat.76, 444–460 (1922).
Bunney, W. E., D. S. Janowsky, F. K. Goodwin, J. M. Davis, M. K. H. Brodie, D. L. Murphy, andT. N. Chase: Effect of L-DOPA on depression. LancetI, 885–886 (1969).
Bürger, H., andW. Mayer-Gross: Schizophrene Psychosen bei Encephalitis lethargica. Z. Neurol. Psychiat.106, 438–482 (1926).
Calne, D. B., A. S. D. Spiers., G. M. Stern, D. R. Laurence, andR. Armitoge: L-DOPA in idiopathic parkinsonism. Lancet2, 973–976 (1969).
Carlsson, A., M. Lindqvist, T. Magnusson, andB. Waldeck: On the presence of 3-hydroxytyramine in brain. Science127, 471–473 (1958).
Celesia, G. G., andA. N. Barr: Psychosis and other psychiatric manifestations of levodopa therapy. Arch. Neurol.23, 193–200 (1970).
Cherrington, M.: Parkinsonism, L-DOPA and mental depression. J. Americ. Geriat. Soc.18, 513–516 (1970).
Clark, W. G.: Some aspects of the psychic and behavioral effects of L-DOPA. p. 349–357. In: L-DOPA and Parkinsonism (Barbeau, A., andF. H. McDowell, eds.). Philadelphia: Fa. Davis. 1970.
Coppen, A., D. M. Shaw, A. Mallerson, E. Eccleston, andG. Gundy: Tryptamine metabolism in depression.Brit.J.Psychia.111, 993–998 (1965).
Coppen, A., D. M. Shaw, B. Herzberg, andR. Maggs: Tryptophan in the treatment of depression. Lancet2, 1178–1180 (1967).
Cotzias, G. C., M. H. van Woert, andL. M. Schiffer: Aromatic amino acids and modification of parkinsonism. New Eng. J.Med.276, 374–379 (1967).
Cotzias, G. C., D. S. Papavasiliou, andR. Gellen: Modification of parkinsonism: chronic treatment with L-DOPA. New Eng. J. Med.280, 337–345 (1969).
Damasio, A. R., J. L. Antunes, andC. Macedo: L-DOPA, Parkinsonism and Depression. LancetII, 611–612 (1970).
Domarus, E.: Über halluzinatorisch-paranoide Bilder bei Metencephalitis. Arch. Psychiatr.78, 558–570 (1926).
Economo, C. v.: Die Encephalitis lethargica, ihre Nachkrankheiten und ihre Behandlung. Wien: Urban <Schwarzenberg. 1929.
Ehringer, H., andO. Hornykiewicz: Verteilung von Noradrenalin und Dopamin (3-Hydroxytryptamin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr.38, 1236–1240 (1960).
Euler, V. S. v.: A specific Sympathomimetic Ergone in Adrenergic Nerve Fibres and its Relations to Adrenaline and Nor Adrenaline. Acta Physiol. Scand.12, 73–97 (1946).
Everett, G. M., andJ. W. Borcherding: L-DOPA: Effect on Concentrations of Dopamine, Norepinephrine and Serotonin in Brains of Mice. Science6, 849–850 (1970).
Goodwin, F. K., H. K. H. Brodie, D. L. Murphy, andW. E. Bunney: Administration of a peripheral decarboxylase inhibitor with L-DOPA to depressed patients. LancetI, 908–911 (1970).
Goodwin, F. K.: Psychiatric Side Effects of Levodopa in Man. JAMA218, 1915–1919 (1971).
Jenkins, R. B., andR. H. Groh: Mental symptoms in Parkinsonian patients treated with L-DOPA. LancetII, 177–180 (1970).
König, H.: Zur Psychopathologie der Paralysis agitans. Arch. Psychiatr.50, 285–305 (1912).
Lenz, H.; Die Dissoziation der Schlafkomponenten beim Parkinsonsyndrom. Arch. Psychiatr.194, 550–559 (1956).
Leonhard, K.: Partielle Schlaf zustände mit Halluzinationen beim Parkinson. Z. Neur.131, 234–264 (1931).
Leyser, E.: Über die Differentialdiagnose metencephalitischer und schizophrener Störungen. Z. Neur.99, 424–438 (1929).
Lhermitte, J.: Syndrome de la calotte du pédoncule cérébral. Rev. neurol.38, 1359–1365 (1922).
Malitz, S., andM. Kanzler: L-DOPA-Behavioural Effects. In:Ajuriaguerra, J. de: Symposium Bel-Air IV. Monoamines noyaux gris centraux et Syndrome de Parkinson, p. 467–484. Paris: Masson. 1971.
Maillé, A. H.: Les troubles psychiques chez les parkinsoniens. Thèse Bordeaux. 1908.
Matussek, N., O. Benkert, K. Schneider, H. Otten, andH. Pohlmeier: L-DOPA plus Decarboxylase Inhibitor in Depression. LancetII, 660–661 (1970).
McDowell, F., J. E. Lee, T. Swift, R. D. Sweet, J. S. Ogsbury, andJ. T. Kessler: Treatment of Parkinson's syndrome with L-dihydroxyphenylalanine (levodopa). Ann. Intern. Med.72, 29–35 (1970).
Meunter, M. D.: Double-blind placebo-controlled study of levodopa therapy in Parkinson's disease. Neurology20, 6–13 (1970).
Ng, K. Y., T. N. Chase, R. W. Cobitrn, andI. J. Kopin: L-DOPA-induced release of cerebral monoamines. Science170, 76–77 (1970).
O'Brien, C. P., J. N. DiGiacomo, S. Fahn, andG. A. Schwarz: Mental Effects of High-Dosage-Levodopa. Arch. Gen.Psychiat.24, 61–64 (1971).
Schildkraut, J. J.: The catecholamine hypothesis of affective disorders. Amer. J. Psychiat.123, 508–522 (1965).
Siegfried, J.: Traitement du Parkinsonisme avec la L-DOPA associée à un inhibiteur de la decarboxylase. Méd. et Hyg.27, 543–545 (1969).
Timberlake, W. H.: Double-blind comparison of levodopa and procyclidine in Parkinsonism. Neurology20, 31–35 (1970).
Tissot, R., J. M. Gaillard, M. Guggisberg, G. Gauthier, andJ. Ajuriaguerra: Therapeutique du syndrome de Parkinson par la L-DOPA “per os” associée à un inhibiteur de la décarboxylase (Ro 4-4602). Press méd.77, 616–622 (1969).
Twarog, B. M., andJ. H. Page: Serotonin Content of some Mammalian Tissues and Urine and a Method for its Determination. J. Physiol.175, 157–161 (1953).
Vogt, M.: The concentration of sympathin in different parts of the central nervous system. J. Physiol.123, 451–481 (1954).
Yahr, M. D., R. S. Duvoisin, M. J. Schear, R. E. Barret, andM. M. Hoehn: Treatment of Parkinsonism with levodopa. Arch. Neurol. (Chic.)21, 343–354 (1969).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Birkmayer, W., Danielczyk, W., Neumayer, E. et al. The balance of biogenic amines as condition for normal behaviour. J. Neural Transmission 33, 163–178 (1972). https://doi.org/10.1007/BF01260902
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01260902